[go: up one dir, main page]

MX2018014937A - Anticuerpos anti-pd-1, un metodo de produccion y un metodo para su uso. - Google Patents

Anticuerpos anti-pd-1, un metodo de produccion y un metodo para su uso.

Info

Publication number
MX2018014937A
MX2018014937A MX2018014937A MX2018014937A MX2018014937A MX 2018014937 A MX2018014937 A MX 2018014937A MX 2018014937 A MX2018014937 A MX 2018014937A MX 2018014937 A MX2018014937 A MX 2018014937A MX 2018014937 A MX2018014937 A MX 2018014937A
Authority
MX
Mexico
Prior art keywords
antibodies
same
oncology
producing
human
Prior art date
Application number
MX2018014937A
Other languages
English (en)
Inventor
Vladimirovna Goncharova Olga
Aleksandrovich Nemankin Timofey
Valentinovich MOROZOV Dmitry
Borisovich ULITIN Andrei
Iurevich USTIUGOV Iakov
Valeryevich KORZHAVIN Dmitry
Alekseevich Ivanov Roman
Mikhailovna EKIMOVA Viktoriia
Sergeevna Chernykh Yulia
Vladimirovich Solovyev Valery
Konstantinovna VLADIMIROVA Anna
Andreevna Bulankina Irina
Vasilyevich Diduk Sergei
Vladimirovna Eroshova Anna
Vladimirovna Artiukhova Marina
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MX2018014937A publication Critical patent/MX2018014937A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a biotecnología y comprende anticuerpos monoclonales aislados, en particular, anticuerpos monoclonales humanos, que se unen específicamente a PD-1 con alta afinidad. Los anticuerpos de acuerdo con la invención pueden ser anticuerpos quiméricos, humanizados o humanos, o fragmentos de unión a antígeno de los mismos, y pueden usarse como un agente medicinal en oncología e inmunoncología, para tratar enfermedades asociadas con varios trastornos de desarrollo o proliferación celular. La invención se refiere también a los métodos para producir dichos anticuerpos y un método para tratar enfermedades humanas mediante el uso de dichos anticuerpos.
MX2018014937A 2016-07-13 2017-07-04 Anticuerpos anti-pd-1, un metodo de produccion y un metodo para su uso. MX2018014937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016128487A RU2656181C1 (ru) 2016-07-13 2016-07-13 Анти-pd-1-антитела, способ их получения и способ применения
PCT/RU2017/050056 WO2018013017A1 (ru) 2016-07-13 2017-07-04 Анти-pd-1-антитела, способ их получения и способ применения

Publications (1)

Publication Number Publication Date
MX2018014937A true MX2018014937A (es) 2019-05-16

Family

ID=60953256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014937A MX2018014937A (es) 2016-07-13 2017-07-04 Anticuerpos anti-pd-1, un metodo de produccion y un metodo para su uso.

Country Status (21)

Country Link
US (1) US11136408B2 (es)
EP (1) EP3486257A4 (es)
JP (1) JP6993992B2 (es)
KR (1) KR102482710B1 (es)
CN (1) CN110023335B (es)
BR (1) BR112019000436A2 (es)
CA (1) CA3021372A1 (es)
CL (1) CL2018003407A1 (es)
CO (1) CO2019001246A2 (es)
CR (1) CR20190009A (es)
EC (1) ECSP19010852A (es)
JO (1) JOP20190002A1 (es)
MA (1) MA44547B1 (es)
MX (1) MX2018014937A (es)
NI (1) NI201900002A (es)
NZ (1) NZ750221A (es)
PE (1) PE20190450A1 (es)
PH (1) PH12018550179A1 (es)
RU (1) RU2656181C1 (es)
WO (1) WO2018013017A1 (es)
ZA (1) ZA201900792B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA121914C2 (uk) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Молекула, що зв'язує pd1 і lag3
CN110382536B (zh) 2017-01-20 2023-12-19 大有华夏生物医药集团有限公司 抗pd-1抗体及其用途
US11203611B2 (en) 2017-04-14 2021-12-21 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
SI3661954T1 (sl) 2017-08-03 2022-05-31 Amgen Inc. Muteini interlevkina-21 in postopki zdravljenja
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
US12258407B2 (en) 2018-07-19 2025-03-25 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-PD-1 antibodies, dosages and uses thereof
CN109652453B (zh) * 2018-12-29 2021-04-06 杭州科兴生物科技有限公司 一种基于pd-1/pdl-1阻断功能及生物效应的抗癌药物快速筛选方法
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
US20220275088A1 (en) * 2019-06-14 2022-09-01 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
TWI844666B (zh) * 2019-08-22 2024-06-11 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
KR20220162130A (ko) 2020-02-28 2022-12-07 탈락 테라퓨틱스, 인크. 트랜스글루타미나제-매개된 접합
PL4157876T3 (pl) 2020-05-26 2025-02-03 Boehringer Ingelheim International Gmbh Przeciwciała anty-pd-1
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
US20250270320A1 (en) * 2020-12-10 2025-08-28 Eutilex Co., Ltd. Anti-pd-1 antibody and uses thereof
MX2023011663A (es) * 2021-03-31 2023-10-11 Merus Nv Dominios de union a pd-1 novedosos.
BR112023020856A2 (pt) 2021-04-08 2024-02-06 Biocad Joint Stock Co Uso de anticorpo para pd-1 e método de tratamento para uma neoplasia maligna
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2024077069A1 (en) * 2022-10-05 2024-04-11 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2691357C (en) * 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
US8062852B2 (en) * 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CA2778714C (en) * 2009-11-24 2018-02-27 Medimmune Limited Targeted binding agents against b7-h1
US8993731B2 (en) * 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
KR101614195B1 (ko) * 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
HUE053069T2 (hu) * 2013-05-02 2021-06-28 Anaptysbio Inc Programozott halál-1 (PD-1) ellen irányuló ellenanyagok
PT3702373T (pt) * 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
PL3177640T3 (pl) * 2014-08-08 2020-11-02 The Board Of Trustees Of The Leland Stanford Junior University Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
GB201419084D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Also Published As

Publication number Publication date
KR20190029641A (ko) 2019-03-20
CA3021372A1 (en) 2018-01-18
AU2017297138A8 (en) 2019-02-28
CO2019001246A2 (es) 2019-02-19
PE20190450A1 (es) 2019-03-29
JP6993992B2 (ja) 2022-01-14
ECSP19010852A (es) 2019-06-30
CN110023335A (zh) 2019-07-16
EP3486257A4 (en) 2020-03-04
BR112019000436A2 (pt) 2019-10-01
WO2018013017A1 (ru) 2018-01-18
US20190127478A1 (en) 2019-05-02
KR102482710B1 (ko) 2023-01-02
MA44547B1 (fr) 2021-09-30
JOP20190002A1 (ar) 2019-01-10
AU2017297138A2 (en) 2019-02-21
CL2018003407A1 (es) 2019-03-29
ZA201900792B (en) 2020-03-25
NI201900002A (es) 2019-06-11
NZ750221A (en) 2022-09-30
AU2017297138A1 (en) 2019-02-14
US11136408B2 (en) 2021-10-05
PH12018550179A1 (en) 2019-03-11
CN110023335B (zh) 2024-05-17
MA44547A1 (fr) 2020-01-31
JP2019527543A (ja) 2019-10-03
CR20190009A (es) 2019-06-05
EP3486257A1 (en) 2019-05-22
RU2656181C1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
SG10201900571YA (en) Anti-pd-1 antibodies
SG10201901057UA (en) Anti-pd-l1 antibodies
MY194994A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
NZ759835A (en) Cd38 modulating antibody
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
ZA202008095B (en) Humanized antibodies against psma
MY210018A (en) Monoclonal antibody that binds specifically to gitr
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
TH1901000154A (th) แอนติบอดีต้าน pd-1, วิธีการผลิตและวิธีการใช้ของสิ่งดังกล่าว
BR112016022013A2 (pt) anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15) e usos dos mesmos para tratamento de caquexia do câncer e câncer